Integrated efficacy and safety results from SPIRIT-P1 an SPIRIT-P2, two phase 3 trials of ixekizumab for the treatment of psoriatic arthritis / Combe B. ... [et al.]. Dermatológia pre prax Roč. 12, č. 3 (2018), s. 147-148